8 Dec

Recent Developments at Johnson & Johnson

WRITTEN BY Mike Benson

Recent developments

As we discussed earlier, Johnson & Johnson’s (JNJ) 3Q16 segment-wise performance was positive at the operational level across all segments, including Pharmaceuticals, Consumer, and Medical Devices segments.

However, the Consumer segment reported a decline in revenues, as the negative impact of foreign exchange more than offset the operational growth. The major developments for JNJ during 3Q16 include the following:

Recent Developments at Johnson & Johnson

Pharmaceuticals segment

Some recent developments for the Pharmaceuticals segment are as follows:

  • On November 21, 2016, the FDA approved Darzalex in combination with two standard care treatments, including lenalidomide and dexamethasone (or bortezomib and dexamethasone), for the treatment of previously treated patients with multiple myeloma.
  • On November 15, 2016, the European Commission approved Stelara for the treatment of active Crohn’s disease.
  • On October 10, 2016, Piramal Healthcare UK Ltd. announced the acquisition of five anesthesia and pain management products from Belgium-based Janssen for $175 million. The products include Sublimaze, Sufenta, Rapifen, Dipidolor, and Hypnomidate brands.
  • The FDA granted breakthrough therapy designation to Esketamine for the treatment of major depressive disorders.
  • The FDA approved label expansion of Invokamet as a first-line treatment for the patients with type 2 diabetes.
  • The FDA approved Stelara for the treatment of the patients with active Crohn’s disease.

Medical Devices segment

  • Johnson & Johnson announced the acquisition agreement for Abbott (ABT) Medical Optics.
  • On October 25, 2016, the FDA approved Evarrest Fibrin Sealant Patch as an adjunctive hemostat to be used to stop bleeding during surgeries.
  • Johnson & Johnson launched Acclarent Aera, the first balloon dilation intervention for Eustachian tube dysfunction in the US.
  • Johnson & Johnson announced divestment of Reach brand’s Asia-Pacific business to LG Household & Healthcare Ltd. in November 2016.

Consumer segment

  • Johnson & Johnson’s (JNJ) Consumer segment completed the acquisition of Vogue International LLC on July 18, 2016, to strengthen its Hair Care and Other Personal Care product portfolio. The deal was worth $3.3 billion.

Abbott’s (ABT) Humira competes with JNJ’s Stelara, while Bristol-Myers Squibb’s (BMY) and Pfizer’s (PFE) Eliquis competes with JNJ’s Xarelto.

Investors can consider the PowerShares S&P 500 Momentum Portfolio ETF (SPMO), which holds 7.6% of its portfolio in Johnson & Johnson.

Latest articles

19 Jul

Afya's IPO Sees Strong Listing Gains

WRITTEN BY Mohit Oberoi, CFA

Afya (AFYA) listed on the Nasdaq Global Select Market on July 19. The company priced its IPO at $19 per share.

19 Jul

What to Watch For in Amazon's Q2 Earnings

WRITTEN BY Sanmit Amin

e-Commerce giant Amazon (AMZN) is scheduled to report its second-quarter earnings results after the closing bell on July 25.

19 Jul

Barrick Gold Reaches Deal to Buy Acacia Mining

WRITTEN BY Anuradha Garg

After a long standoff, Barrick Gold (GOLD) and Acacia Mining (ABGLF) have reached an agreement.

19 Jul

Comcast Shares Pop on Goldman's Optimism

WRITTEN BY Ruchi Gupta

Comcast (CMCSA) shares popped after Goldman Sachs issued a positive note on the company recently. Goldman upgraded its rating for Comcast to "buy" from "hold."

19 Jul

Why Analysts Are Bearish on Netflix Stock

WRITTEN BY Aditya Raghunath

Netflix stock fell over 10.0% on Thursday and is down 0.5% today as well.

On Thursday, pet retailer Chewy (CHWY) reported its first-quarter results after the market closed. The company reported its earnings for the first time.